The discovery of a second-generation dual oral inhibitor of PARP1/2 and tankyrase, JPI-547 (Onconic Therapeutics Inc.), exhibited antitumor activity in HR-deficient xenograft models.
Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have discovered new phosphatidylinositol 3-kinase α (PI3Kα) H1047R mutant inhibitors potentially useful for the treatment of cancer, PIK3CA-related overgrowth spectrum (PROS), immune diseases and inflammatory diseases.
Gertrude Biomedical Pty. Ltd. has patented new transcription factor SOX18 inhibitors potentially useful for the treatment of renal disorders, eye disorders and cancer.
Pancreatic ductal adenocarcinoma (PDAC) is still a highly lethal cancer with limited therapeutic options. Its lethality mainly stems from activating KRAS mutations and a metabolic dependence on nicotinamide adenine dinucleotide (NAD). Researchers from Remedy Plan Inc. have presented data on RPT-E-037, which exerts dual targeting of NAD metabolism through Nampt inhibition and KRAS signaling inhibition using a pan-RAS inhibitor (RMC-6236).
Ichnos Glenmark Innovation Inc. has announced a new development candidate, ISB-2301, a potentially first-in-class, multispecific immune cell activator for the potential treatment of multiple solid tumor indications. ISB-2301 is a multispecific antibody that targets three tumor-associated antigens to trigger tumor cell death and engages both T and NK cells to activate the immune system. Leveraging the company’s BEAT technology, ISB-2301 is designed to induce potent antibody-dependent cellular cytotoxicity, checkpoint inhibition and a sustained type 1 immune response.
Shanghai Institute of Materia Medica of the Chinese Academy of Sciences and Yantai New Drug Creation Shandong Laboratory have reported new degrader-antibody-drug conjugates (DACs) potentially useful for the treatment of cancer which are comprised of an antibody covalently bound to a molecular glue degrader moiety.
Inxmed (Nanjing) Co. Ltd. has discovered new focal adhesion kinase (FAK) and focal adhesion kinase 2 (FADK2; PTK2B; PYK2) dual inhibitors potentially useful for the treatment of cancer.
Zhejiang Normal University has patented new inhibitors of proto-oncogene tyrosine-protein kinase receptor Ret (RET; CDHF12; PTC) and its mutants potentially useful for the treatment of cancer.
Matter Bio has submitted its first IND application to the FDA for Lm-LLO-TT, the company’s lead therapeutic candidate, seeking to initiate a first-in-human phase I/IIa trial in patients with pancreatic ductal adenocarcinoma (PDAC).
RSS
